These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 11589823)

  • 1. Comparison of NNRTIs in antiretroviral-experienced patients.
    Maggiolo F
    Int J STD AIDS; 2001 Nov; 12 Suppl 4():10-7. PubMed ID: 11589823
    [No Abstract]   [Full Text] [Related]  

  • 2. The role of NNRTIs in antiretroviral combination therapy: an introduction.
    Nelson M
    Int J STD AIDS; 2001 Nov; 12 Suppl 4():1-2. PubMed ID: 11589821
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of NNRTIs in antiretroviral-naïve patients.
    Arribas J
    Int J STD AIDS; 2001 Nov; 12 Suppl 4():3-9. PubMed ID: 11589822
    [No Abstract]   [Full Text] [Related]  

  • 4. [The use of the non-nucleoside reverse transcriptase inhibitors nevirapine and efavirenz in the treatment of patients with a chronic HIV-I infection].
    van Leth F; Lange JM
    Ned Tijdschr Geneeskd; 2006 Aug; 150(31):1719-22. PubMed ID: 16924943
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Efavirenz--comprehensive status of studies].
    MMW Fortschr Med; 2005 Apr; 147 Spec No 1():79-81. PubMed ID: 16385886
    [No Abstract]   [Full Text] [Related]  

  • 6. Nevirapine or efavirenz combined with two nucleoside reverse transcriptase inhibitors compared to HAART: a meta-analysis of randomized clinical trials.
    Torre D; Tambini R; Speranza F
    HIV Clin Trials; 2001; 2(2):113-21. PubMed ID: 11590519
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors affecting adherence and convenience in antiretroviral therapy.
    Lafeuillade A
    Int J STD AIDS; 2001 Nov; 12 Suppl 4():18-24. PubMed ID: 11589824
    [No Abstract]   [Full Text] [Related]  

  • 8. Other issues: penetration into sanctuary sites, immune reconstitution and NNRTI sequencing.
    Stellbrink HJ
    Int J STD AIDS; 2001 Nov; 12 Suppl 4():25-32. PubMed ID: 11589825
    [No Abstract]   [Full Text] [Related]  

  • 9. [Results of the AIDS-In-Europe Study. Non-nucleoside reverse transcriptase inhibitor does not equal non-nucleoside reverse transcriptase inhibitor].
    MMW Fortschr Med; 2001 Apr; 143 Suppl 1():39. PubMed ID: 11373776
    [No Abstract]   [Full Text] [Related]  

  • 10. Can early failure with nevirapine be rescued with efavirenz?
    Briones C; Soriano V; Dona C; Barreiro P; González-Lahoz J
    J Acquir Immune Defic Syndr; 2000 May; 24(1):76-8. PubMed ID: 10877499
    [No Abstract]   [Full Text] [Related]  

  • 11. HIV/AIDS news: comparable anti-HIV antiviral efficacy of Viramune and Efavirenz--the Lancet publishes first large-scale comparison study.
    Meyer-Kleinmann J
    Infection; 2004 Jun; 32(3):7. PubMed ID: 15230276
    [No Abstract]   [Full Text] [Related]  

  • 12. Non-nucleoside reverse transcriptase inhibitors--an overview.
    Bell C; Matthews GV; Nelson MR
    Int J STD AIDS; 2003 Feb; 14(2):71-7. PubMed ID: 12662384
    [No Abstract]   [Full Text] [Related]  

  • 13. Nevirapine plus efavirenz plus didanosine: a simple, safe, and effective once-daily regimen for patients with HIV infection.
    Jordan WC; Jefferson R; Yemofio F; Tolbert L; Conlon V; Carroll H; Green DC; Green A; Green R
    J Natl Med Assoc; 2003 Dec; 95(12):1152-7. PubMed ID: 14717471
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NNRTI hepatotoxicity: efavirenz versus nevirapine.
    Pulido F; Torralba M
    J HIV Ther; 2002 Nov; 7 Suppl 2():S3-16. PubMed ID: 12735215
    [No Abstract]   [Full Text] [Related]  

  • 15. NNRTIs: a neglected class.
    Cadman J
    GMHC Treat Issues; 1998 Sep; 12(9):6-10. PubMed ID: 11365807
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Simplification of protease inhibitor-containing regimens with efavirenz, nevirapine or abacavir: safety and efficacy outcomes.
    Chiesa E; Bini T; Adorni F; Capetti A; Rizzardini G; Faggion I; Mussini C; Sollima S; Melzi S; Bongiovanni M; Tordato F; Cicconi P; Castelnuovo B; Rusconi S; d'Arminio Monforte A
    Antivir Ther; 2003 Feb; 8(1):27-35. PubMed ID: 12713061
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The tolerability of efavirenz after nevirapine-related adverse events.
    Clarke S; Harrington P; Barry M; Mulcahy F
    Clin Infect Dis; 2000 Sep; 31(3):806-7. PubMed ID: 11017835
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Combined antiretroviral therapy with nevirapine of HIV-infected adults].
    Kravchenko AV
    Ter Arkh; 2004; 76(11):68-71. PubMed ID: 15658542
    [No Abstract]   [Full Text] [Related]  

  • 19. Hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in HIV-1.
    Moreno S; Casado JL; Pérez-Elías MJ; Dronda F; Antela A; Moreno A; Gutiérrez C
    AIDS; 2003 Jun; 17(9):1413-4. PubMed ID: 12799573
    [No Abstract]   [Full Text] [Related]  

  • 20. Higher virological effectiveness of NNRTI-based antiretroviral regimens containing nevirapine or efavirenz compared to a triple NRTI regimen as initial therapy in HIV-1-infected adults.
    Pérez-Elías MJ; Moreno A; Moreno S; López D; Antela A; Casado JL; Dronda F; Gutiérrez C; Quereda C; Navas E; Abraira V; Rodríguez MA
    HIV Clin Trials; 2005; 6(6):312-9. PubMed ID: 16452065
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.